In an article published in Cell Host & Microbe on March 3, 2026, researchers at McMaster University in Canada and at the Hospital Universitario de La Princesa in Spain have shed some light on the impact of microbiota on peanut-driven allergy and anaphylaxis. Read More
Entering its first major cardiovascular disease collaboration with a biopharma company, while it advances two internal gene therapies, Tenaya Therapeutics Inc. signed on with Alnylam Pharmaceuticals Inc. to deliver up to 15 novel genetic targets that could lead to new heart disease medicines. The deal comes with $10 million up front, and up to $1.13 billion is available to South San Francisco-based Tenaya if all targets meet certain milestones, leading to approved therapeutics that Alnylam develops and commercializes. Read More
Kestrel Therapeutics Inc. has obtained IND approval from the FDA for KST-6051, an oral, small-molecule pan-KRAS inhibitor being developed for the treatment of KRAS-driven cancers. Read More
Researchers at Shenyang Pharmaceutical University reported the discovery and preclinical evaluation of a PDE4 inhibitor as a potential treatment for chronic obstructive pulmonary disease. Read More
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy. Read More
Great Novel Therapeutics Biotech & Medicals Corp.’s epigenetic immunoactivator, GNTbm-38, has received IND clearance from the FDA, enabling initiation of a phase I trial in the U.S. Read More
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis of Parkinson’s disease. Read More
Approximately 10%-15% of breast cancer cases are classified within the invasive lobular carcinoma (ILC) type, and a great majority of them are estrogen receptor-positive (ER+). Despite the significant clinical differences between ILCs and invasive carcinoma of no special type (or ductal), ICL treatment still follows ductal paradigms, relying on endocrine therapy plus surgery and radiotherapy. Read More
A patent from Gilead Sciences Inc. has divulged GTPase KRAS (G12D mutant) inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety through linker. Read More
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed amide-substituted cycloalkyl compounds acting as relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of heart failure and hypertension. Read More
China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals. Read More
B-cell acute lymphoblastic leukemia (B-ALL), characterized by the clonal expansion of immature lymphoblastic cells, is traditionally treated with lengthy chemotherapy followed by allogeneic stem cell transplantation (aSCT) for high-risk patients. However, patients with relapsed or refractory B-ALL still present a dismal prognosis. Read More
